Sarah B. Gitto

Also affiliated with Philadelphia University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma”.

Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

Communications Biology(2022)10.1038/s42003-022-04209-8

N/A

0.489DataRank · unranked

25 citations

Minu Samanta, Paul Martorano, Hwan Lee, Sarah B. Gitto, Khushbu Patel +18 more

Induction of pancreatitis in mice with susceptibility to pancreatic cancer

Methods in cell biology(2022)10.1016/bs.mcb.2021.12.013

N/A

0DataRank · unranked

6 citations

Sai Preethi Nakkina, Jordan M. Beardsley, Jignesh Parikh, Deborah A. Altomare, Sarah B. Gitto

885 Enhancing immune checkpoint inhibitor efficacy with anti-angiogenics in ovarian cancer

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0885

N/A

0DataRank · unranked

0 citations

S. P. Medvedev, Veethika Pandey, Dalia K. Omran, Matthew Anderson, Lauren E. Schwartz +3 more

A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1079

N/A

0DataRank · unranked

34 citations

Margaret Whicker, Gareth Davies, Sushil Kumar, Krista Kinneer, Haineng Xu +13 more

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-006533

N/A

0DataRank · unranked

20 citations

David A. Braun, Aitziber Buqué, Sarah B. Gitto, Jennifer L. Guerriero, Brendan Horton +9 more

Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer

Research Square(2023)10.21203/rs.3.rs-3314138/v1

N/A

0DataRank · unranked

2 citations

Yasuto Kinose, Haineng Xu, Hyoung Kim, Sushil Kumar, Xiaoyin Shan +19 more

Adoptive T cell therapy for ovarian cancer

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.04.001

N/A

0DataRank · unranked

27 citations

Chibuike Ihewulezi, Daniel J. Powell, Sarah B. Gitto

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer

iScience(2024)10.1016/j.isci.2024.109978

N/A

0DataRank · unranked

12 citations

Sarah B. Gitto, Gwo‐Yaw Ho, Sergey Medvedev, Kristy Shield‐Artin, Hyoung Kim +15 more

CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.01.029

N/A

0DataRank · unranked

8 citations

Monika A. Eiva, Fang Liu, Dalia K. Omran, Stefan Gysler, Erica Brown +7 more

PARP1-targeted alpha therapy enhances target expression

EJNMMI Research(2025)10.1186/s13550-025-01256-0

N/A

0DataRank · unranked

2 citations

Paul Martorano, Hsiaoju Lee, Shuyao Geng, Vandana Batra, John M. Maris +4 more

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1602

N/A

0DataRank · unranked

32 citations

Sarah B. Gitto, Mehran Makvandi, Hyoung Kim, Sergey Medvedv, Joanna K. Weeks +16 more

Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace

International Journal of Radiation Oncology*Biology*Physics(2025)10.1016/j.ijrobp.2025.05.085

N/A

0DataRank · unranked

1 citations

Daniel Suárez-García, Jesús J. Bosque, Hwan Lee, Fiona Simpkins, Sarah B. Gitto +3 more